Background: Erratic tacrolimus blood levels are associated with liver and kidney graft failure. We
ERRATIC TACROLIMUS EXPOSURE, ASSESSED USING STANDARD DEVIATION OF TROUGH BLOOD LEVELS
Chronic loss of allograft function is the major cause of morbidity and mortality after transplantation and its prevention rightly remains one of the main focuses of post-transplant care. In the lung, this process is now termed chronic lung allograft dysfunction (CLAD) and is characterised by a permanent 20% decline in FEV 1 over the best achieved post-transplant. CLAD is associated with reduced quality of life and increased mortality following lung transplantation (1) (2) (3) (4) (5) (6) . Acute rejection remains the most important risk factor (7) .
The currently available immunosuppressive agents (typically a corticosteroid, a cell cycle inhibitor and a calcineurin inhibitor) are generally very effective at preventing the development of acute rejection if therapeutic drug levels can be reached (6, (8) (9) (10) . Of these agents, cyclosporine led to the biggest stepchange in the success of solid organ transplantation, with more recent evidence supporting a slight advantage for tacrolimus over cyclosporine in lung transplantation (11) (12) (13) (14) (15) (16) .
Therapeutic drug monitoring of tacrolimus trough levels is essential to achieve adequate immunosuppression while minimising toxicity. While the mean drug level required to prevent rejection has been well studied, little attention has been paid to the effect of erratic tacrolimus exposure, but with a satisfactory mean, in lung transplantation (15, (17) (18) (19) (20) (21) (22) . There are good reasons to believe that erratic exposure may be just as deleterious as sub-therapeutic tacrolimus exposure, but this possibility has been little explored. High tacrolimus trough level variability (assessed using standard deviation (SD)) increases the risk of acute rejection early post adult lung transplant but its affect on CLAD and survival are unknown (23) . In the liver and kidney transplant literature, an association has been found between high intra-patient tacrolimus level variability and late graft failure (24) (25) (26) . This has not been assessed in adult lung transplant recipients. We aimed to assess the effect of mean tacrolimus trough level as well as variation in tacrolimus trough levels, assessed using SD, on the development of CLAD and survival following adult lung transplantation. We also aimed to identify factors which influence tacrolimus trough level variability. food. Target trough levels were 5-15 g/l (10-15 g/l for 0-6 months followed by 5-10 g/l from 6 months).
Individual target ranges varied, taking into account history of rejection, infection and other side-effects, but not pre-transplant diagnosis. Tacrolimus dose adjustments for CF patients were made as for the non-CF cohort. Oral pancreatic enzyme replacement was provided to those CF patients with pancreatic insufficiency. Tacrolimus monitoring was performed 3 times/week for the first 2 weeks post transplant, then twice weekly for 4 weeks, weekly for 1 month and then fortnightly for 1 month. For patients with stable levels further blood draws were performed monthly up until 6 months and then 3 monthly thereafter. Levels were checked 3-4 days following tacrolimus dose adjustments and twice weekly for inpatients.
Collected data included patient demographics, date of transplant, time post-transplant or date of death, disease indication for transplant, type of transplant and tacrolimus blood trough levels. Acute rejection burden was assessed by summing the A grades in the first 12 months. CLAD was defined as a 20% fall from best post-transplant FEV1 as per the evolving International Society of Heart and Lung Transplant (ISHLT) guidelines (27) . Respiratory function tests were performed at 2 weeks post transplant and then twice weekly for 4 weeks, weekly for 1 month, fortnightly for 1 month and then 3 monthly thereafter. Patients performed daily home spirometry and were instructed to present to clinic if they had a reduction of 10%.
Tacrolimus trough levels were measured as part of routine post transplant care in both inpatients and outpatients by two pathology providers using liquid chromatography-tandem mass spectrometry (LC- 
Results

Cohort Characteristics
110 subjects, median age 41.3 (IQR 27.6 -51.6) years were included. Table 1 displays the baseline characteristics. 56% of subjects were female, 87% had bilateral transplants, and the indications for transplant were cystic fibrosis (CF, 47%), chronic obstructive pulmonary disease (COPD, 26%), pulmonary fibrosis (8%) and other (21%). Median follow up was 60 (30.6-95.7) months. At census 37 patients (34%)
were deceased and 48 (44%) had developed CLAD.
Tacrolimus Mean and SD
Tacolimus SD The median number of tacrolimus measurements per patient for the 0-6, 6-12 and 12-24 month periods were 15 (IQR 8 -24), 11 (7-17, range 2-30 measurements) and 13 (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) respectively. There was a positive correlation between the number of tacrolimus measurements and trough level SD (r = 0.489 p<0.001, Figure 3 ) but not with the mean (p=0.698).
Predictors of Tacrolimus SD
Neither the 6-12mth mean tacrolimus level nor the standard deviation were associated with demographic factors, the sum of A grade rejection, transplant type or disease indication (including a diagnosis of cystic fibrosis, Supplementary Table 1) .
Predictors of CLAD and death
No demographic factors were associated with CLAD or death, however a history of acute rejection increased the risk of both CLAD and death ( respectively. In order to exclude the possibility that inpatients, who may be sicker and also have more tacrolimus blood draws perhaps thus affecting the SD, may confound our findings, we repeated the analysis after excluding tacrolimus levels taken from inpatients. Even after excluding these levels, tacrolimus SD from 6-12 months remained a strong independent predictor of time to CLAD (HR 1. 57, CI 1.29 -1.93, P<0.001) and death (HR 1.36, CI 1.09 -1.70, P=0.006).
Discussion
In this retrospective, single-centre cohort study we found that both lower mean and higher standard deviation of tacrolimus levels, assessed between 6 and 12 months post-transplant, independently predicted time to the development of CLAD, with the standard deviation also predicting mortality.
Identifying those patients most at risk of developing chronic rejection and premature death post transplant is one of the key challenges facing treating physicians. This study is important as it is the first to assess the effect of tacrolimus trough level variability on the incidence of CLAD or survival in the setting of adult lung transplantation. While much attention is paid to the attainment of satisfactory tacrolimus levels after transplant, little attention is paid to the variability of those levels. We postulate that patients with fluctuating tacrolimus trough levels are more likely to have levels outside of the therapeutic range predisposing them to immune mediated rejection, toxicity (including nephrotoxicity) and infection. These findings are clinically relevant since tacrolimus SD is simple to calculate and predicts subsequent graft loss and mortality, providing an opportunity for this new knowledge to rapidly translate into better graft and patient outcomes in a highly cost-effective manner. Our results suggest that at the end of the first posttransplant year, assessing the tacrolimus SD may identify patients with erratic levels who are at high risk for subsequent CLAD and/or death.
The first 6 months post transplant is often complicated by more frequent use of high dose steroids (for acute rejection), triazole antifungal prophylaxis and gastrointestinal factors (including gastroparesis) which may affect absorption or metabolism of tacrolimus. These difficulties are reflected in the high tacrolimus level SD during this period. However our data suggest that the erratic tacrolimus exposure during this period does not impact on long term outcomes. In this respect, the 6-12 month period was found to be particularly important as a high tacrolimus SD during this period both predicted a persistently high SD in the second post-transplant year and poor outcome. Collectively our data suggest that there are a subgroup of individuals who have persistently high variability in tacrolimus levels across the life of their transplant and that these individuals could be readily identified before their outcome is compromised.
Our work expands on previous studies that have looked for an association between tacrolimus level SD and acute rejection in adult lung transplant recipients as well as chronic rejection and graft failure in other solid organ transplants. We found no association between acute rejection and tacrolimus SD. Chiang et al, on the other hand, found a 23% increase risk of acute rejection for each 1 unit rise in tacrolimus trough level SD in the first 8-90 days post transplantation (23) . In adult kidney transplant recipients, high within patient variability in tacrolimus clearance (estimated by correcting the blood trough level for the oral dose) in the 6-12 month period was found to increase the risk of graft failure and rejection after 12 months (24).
Further, Pollock-BarZiv's group assessed tacrolimus level variability using SD in paediatric solid organ (including 15 lung) transplant recipients finding a threshold of 2 SD, above which there was increased risk of late rejection and graft loss (26) . Venkat et al also found a 2 SD threshold above which there was an increased risk of late rejection in their paediatric liver transplant cohort (29) . We chose to assess our standard deviation data as a continuous variable and found that for each one unit increase in SD, the time to CLAD or death increased by 46% and 27% respectively, implying that even small increases in SD can adversely affect outcome.
There are a multitude of factors which may cause highly variable tacrolimus trough levels beyond the early post-transplant period. For a given patient, the oral bioavailability of tacrolimus can vary greatly from dose to dose (30) . One particular group of interest are those with CF who have a unique gastrointestinal pathology with significant risk of variability in absorption. Chiang et al proposed that tacrolimus absorption may affect tacrolimus level SD in those with CF. In their cohort of 99 lung transplant recipients (<3 months post transplant), those that developed acute rejection had higher pre-rejection tacrolimus level SD and were made up of a higher proportion of patients with CF (23). However, our findings did not reflect this, with no association between indication for transplant, or indeed any demographic factor, and tacrolimus variability, CLAD or survival. Given that poor adherence to post-transplant care is well known to compromise outcomes, we believe it is likely that poor adherence to the prescribed tacrolimus dosing schedule will explain at least some of the variability in tacrolimus exposure in our cohort. Non-adherance to the dose, the dosing interval, the requirement to take tacrolimus without food, or the timing of blood draws could all contribute to increased tacrolimus SD. In this respect, tacrolimus SD may be an excellent surrogate not only for tacrolimus exposure, but also the ability and/or willingness to follow relatively complicated medical advice. Although adherence is generally high in lung transplant recipients, poor adherence has been shown to be associated with a greater tacrolimus level SD in liver transplant recipients (25, 31) . The relationships between tacrolimus SD, more conventional measures of adherence, and transplant outcomes will be a key focus of future studies.
Pharmacogenomic factors may play a role in determining tacrolimus level mean but little consideration has been paid to its effect on intra-patient variability. Previous studies have found that gene polymorphisms, particularly in CYP3A5, affect tacrolimus concentration-dose relationships, so predicting initial dose requirements in lung transplant recipients (32) (33) (34) . In kidney transplant recipients, a polymorphism of CYP3A5 was found to be a risk factor for acute rejection and nephrotoxicity (35) . Single nucleotide polymorphism analysis of 240 Chinese kidney transplant recipients has revealed a number of other polymorphisms affecting tacrolimus metabolism (36) . Another future direction in lung transplantation may involve SNP analysis to identify patients more susceptible to variable tacrolimus levels or low mean, possibly improving preoperative risk stratification and outcomes.
Variable or reduced exposure to other medications may provide an alternate explanation for the association between tacrolimus SD, CLAD and survival. Other medications (including concurrently prescribed immunosuppressants) are often affected by similar factors including adherence, absorption and metabolism. While it is possible, indeed likely, that high tacrolimus SD acts as a surrogate for variable exposure to other medication, most of the other commonly prescribed drugs have a wider therapeutic window so that variability in drug exposure may be expected to have less of an impact on long-term outcome. Indeed in the study by Borra et al there was no association between variability in mycophenolate clearance and graft failure (24) .
We believe it is likely that our findings will be able to be generalized to other lung transplant cohorts since our cohort's characteristics are similar to those in most transplant centres, except for a slightly higher proportion of patients transplanted for CF. However we do acknowledge some limitations. Given the retrospective design of the study, the timing of tacrolimus levels post dose may have varied, thus potentially affecting both SD and mean. However, the 'real-world' nature of a retrospective study will capture this kind of variability, which in itself may be an important measure of the patient's ability to ensure accurate timing of blood draws, and to follow other relatively complicated, but vital, components of post-transplant care. Although there were some changes in transplant protocols during the 17-year study period (specifically the introduction of basiliximab induction and azithromycin prophylaxis) these agents are not known to significantly alter tacrolimus metabolism (37). Furthermore we saw no era effect when we specifically tested the possibility that historical changes in transplant practice may systematically alter tacrolimus SD or mean. The correlation between number of tacrolimus measurements and trough level SD is an uncontrolled potential confounder. It is possible that more frequent assessment of levels in sicker patients resulted in more frequent dose adjustment with increased variability. However when inpatients (often sicker, having more frequent levels) were removed from the analysis, the SD and mean were not substantially different, and tacrolimus SD still predicted CLAD and death. In fact the relationship between medical monitoring and scheduling of blood draws on adherence to the prescribed tacrolimus schedule is likely complex and potentially unpredictable. For instance it is possible that less adherent, sicker patients may take medications reliably only immediately prior to blood draws thus increasing variability. Conversely one could envisage a different outcome, with adherence and variability improving with more frequent levels as individuals improve behaviour in response to their awareness of being observed (the Hawthorne Effect). However, perhaps the most obvious mode of confounding -that a non-adherent patient at risk of poor outcome may undergo fewer blood tests and therefore have a higher SD -can be excluded since tacrolimus SD was a positive function of the number of observations. In summary, although we believe the observed association between high tacrolimus SD and poor outcome is robust, our study does not provide insight into potential mechanisms.
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In conclusion, patients with highly variable trough tacrolimus levels in the second half of the first posttransplant year will likely have similar variability in the second year and are at high risk for subsequent CLAD and death. Calculating the tacrolimus SD, identifying those with a high SD, and modifying factors contributing to it would seem pertinent objectives at the one year post-transplant anniversary. Specifically targeting these individuals to identify and correct any factors which may be contributing to erratic levels may significantly improve their outcome and survival.
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